Disulfiram plus copper and liposomal chemotherapy for hard-to-treat sarcoma
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests a combination of disulfiram (an anti-alcohol medication), copper, and liposomal doxorubicin (a chemotherapy form) in people with sarcoma that has come back or did not respond to treatment. It aims to shrink or control tumors and improve outcomes when standard options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sarcoma confirmed by biopsy, and it is either relapsed or refractory (not responding).
- Your scans must show measurable tumor spots that can be measured at the start of the study.
- Your body strength is fair-to-good (Karnofsky/Lansky score of 50 or higher).
- Your blood counts and organs must work well enough (enough white cells and platelets, and liver/kidney tests within allowed limits).
- You must be able to swallow the study pills (or take the sprinkled capsule contents with food), and you must be able to follow the study rules and consent process.
- You must not drink alcohol during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called DT-7012 to standard chemotherapy (doxorubicin) works better than chemotherapy alone for two types of advanced soft tissue sarcoma. It aims to see if the combination can shrink tumors or slow their growth.
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
This study tests whether adding an investigational drug called BOLD-100 to a standard chemotherapy (doxorubicin) helps people with certain types of advanced soft tissue sarcoma. It might slow tumor growth or shrink tumors.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Hear when a new Relapsed Sarcomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.